Jennifer Lachey Keros Therapeutics, Inc. (KROS) insider trading activity

Jennifer Lachey is Chief Scientific Officer of Keros Therapeutics, Inc.. Currently has a direct ownership of 95,100 shares of KROS, which is worth approximately $4.35 Million. The most recent transaction as insider was on Nov 10, 2021, when has been sold 15,900 shares (Common Stock) at a price of $60.0 per share, resulting in proceeds of $954,000. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 95.1K

0% 3M change

0% 12M change

Total Value Held $4.35 Million

Jennifer Lachey Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Nov 10 2021	SELL Open market or private sale	$954,000 $60.0 p/Share	15,900 Reduced 15.65%	85,700 Common Stock
Nov 10 2021	BUY Exercise of conversion of derivative security	$4,770 $0.3 p/Share	15,900 Added 13.53%	101,600 Common Stock
Nov 04 2021	SELL Open market or private sale	$530,000 $50.0 p/Share	10,600 Reduced 11.01%	85,700 Common Stock
Nov 04 2021	BUY Exercise of conversion of derivative security	$3,180 $0.3 p/Share	10,600 Added 9.92%	96,300 Common Stock
Aug 17 2021	BUY Exercise of conversion of derivative security	$388 $0.3 p/Share	1,293 Added 1.49%	85,700 Common Stock
Jun 24 2021	BUY Exercise of conversion of derivative security	$1,950 $0.3 p/Share	6,500 Added 7.15%	84,407 Common Stock
Jun 11 2021	SELL Open market or private sale	$136,236 $51.41 p/Share	2,650 Reduced 3.29%	77,907 Common Stock

Jun 11 2021	BUY Exercise of conversion of derivative security	$795 $0.3 p/Share	2,650 Added 3.18%	80,557 Common Stock
May 13 2021	BUY Exercise of conversion of derivative security	$1,411 $0.21 p/Share	6,720 Added 7.94%	77,907 Common Stock
May 11 2021	SELL Open market or private sale	$132,500 $50.0 p/Share	2,650 Reduced 3.59%	71,187 Common Stock
May 11 2021	BUY Exercise of conversion of derivative security	$795 $0.3 p/Share	2,650 Added 3.46%	73,837 Common Stock
Apr 12 2021	SELL Open market or private sale	$320,491 $60.47 p/Share	5,300 Reduced 6.93%	71,187 Common Stock
Apr 12 2021	BUY Exercise of conversion of derivative security	$1,590 $0.3 p/Share	5,300 Added 6.48%	76,487 Common Stock
Apr 01 2021	BUY Exercise of conversion of derivative security	$1,100 $0.11 p/Share	9,996 Added 12.31%	71,187 Common Stock
Mar 11 2021	SELL Open market or private sale	$343,069 $64.73 p/Share	5,300 Reduced 7.97%	61,191 Common Stock
Mar 11 2021	BUY Exercise of conversion of derivative security	$1,590 $0.3 p/Share	5,300 Added 7.38%	66,491 Common Stock
Feb 26 2021	BUY Exercise of conversion of derivative security	$3,652 $0.11 p/Share	33,200 Added 35.17%	61,191 Common Stock
Feb 11 2021	SELL Open market or private sale	$346,832 $65.44 p/Share	5,300 Reduced 15.92%	27,991 Common Stock
Feb 11 2021	BUY Exercise of conversion of derivative security	$1,590 $0.3 p/Share	5,300 Added 13.73%	33,291 Common Stock

Jennifer Lachey

Chief Scientific Officer

Lexington, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells KROS shares.

Notify only if

Value

Insider Trading

Get notified when an Keros Therapeutics, Inc. insider buys or sells KROS shares.

Notify only if

Operation

Value

Type

News

Receive news related to Keros Therapeutics, Inc.

Track Activities on KROS

Account